Teijin Pharma Of Japan To Apply For Clinical Trial Approval Of Gout Drug In China
This article was originally published in PharmAsia News
Executive Summary
Teijin Pharma will apply for clinical trial approval for Uloric (febuxostat, TMX-67) to treat gout and hyperuricemia in China. The Tokyo-based drug and medical maker plans to conduct the trials in China using clinical data used in Europe. Teijin also looks for local Chinese contract research organizations and aims to launch the drug in China through its wholly owned subsidiary Teijin Pharma Shanghai Consulting. Teijin jointly launched Uloric in the U.S. with Tekeda Pharmaceutical North America this March and plans a European market launch this autumn under Adenulic along with French pharmaceutical company Ipsen. This May, Teijin signed grant exclusive licensing rights to Astellas to develop and market the drug in Taiwan. (Click here for more - Japanese language
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.